by rvvadmin | Feb 24, 2022 | 2022
The naturally derived GMP psilocybin will be exported through distribution partner Mycrodose Therapeutics Inc. to the University of Wisconsin-Madison, Contract Research Organization for Revive Therapeutics VANCOUVER, BC, Feb. 24, 2022 – HAVN Life Sciences...
by rvvadmin | Feb 15, 2022 | 2022
TORONTO, Feb. 15, 2022 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to...
by rvvadmin | Feb 14, 2022 | 2022
Ethics Committee approval to proceed with Phase 3 clinical trial in Turkey 13 clinical sites selected to date in Turkey TORONTO, Feb. 14, 2022 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life...
by rvvadmin | Jan 18, 2022 | 2022
701 subjects dosed to date Initiating enrollment activities in Turkey as part of its clinical diversification plans to support global regulatory approvals On-track to complete enrollment in Q1-2022 and FDA submission thereafter Commencing regulatory package activities...
by rvvadmin | Jan 17, 2022 | 2022
IRB approval to initiate Phase 2 study for methamphetamine abuse disorders Advancing psilocybin oral thin film, microneedle patch and biosynthesis programs TORONTO, Jan. 17, 2022 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV)...
